Video Interview: Faron Crosses Finnish Line To Increase Global Footprint
This article was originally published in Scrip
Executive Summary
Having raised £10m floating on London's Alternative Investment Market (AIM) in November 2015, Finland's Faron Pharmaceuticals is planning to establish a more prominent international presence over the next year and a half. President and CEO Dr. Markku Jalkanen explains to Mike Ward, Informa Pharma Insights' global director of content, why the company chose to float in London and how it intends to use the funds to break out of Finland and build a larger global footprint.